Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects

NCT00616655 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

456

Enrollment

INDUSTRY

Sponsor class

Conditions

Generalized Anxiety Disorder

Interventions

DRUG: eszopiclone
DRUG: eszopiclone
DRUG: Placebo

Sponsor

Sumitomo Pharma America, Inc.